Learning Objectives:

1. Discuss the pathogenesis of ILD in systemic sclerosis.

2. Discuss the benefits and harms of nintedanib as a new FDA approved therapeutic option for ILD in systemic sclerosis.

Session date: 
Tuesday, February 4, 2020 - 8:30am to 9:30am
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.